Shots:

• Under the amended agreement- BMS will supply its Opdivo (nivolumab) for Compugen's P-Ib cohort expansion study to evaluate COM701 in combination with Opdivo in selected cancer indications. The study is expected to be initiated in Q2’21
• The P-Ib study will examine fixed doses of COM701 and Opdivo- as determined by Compugen's P-Ia combination dose escalation study. Based on Compugen's translational analyses and preliminary antitumor activity in dose escalation- the study will enroll patients with ovarian- breast- endometrial and microsatellite-stable colorectal cancers
• Additionally- The companies are also investigating COM701 in a triple combination study with Opdivo and BMS-986207

 ­ Ref: PRNewswire | Image: BMS